semaglutide cardiovascular risk GLP-1 receptor agonists can reduce the of adverse events in pts with diabetes. Whether the GLP-1 receptor agonist can also reduce cardiovascular risk in pts with overweight or obesity Effects of semaglutide on risk

^In a multi-national, double-blind clinical trial of over 17,000 patients with BMI of 27 or greater, weekly injections of semaglutide for a mean duration of 33 months reduced the risk of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke by 20%

With the recent introduction of multiple generic variants of GLP-1

Future research should consider age-stratified data to better elucidate potential differential risks

Unlike gastric bypass, this procedure does not alter the small intestine, but it does significantly change how medications are absorbed, tolerated, and processed by the body

Understanding Semaglutide: A Game-Changer in Weight Loss Semaglutide is a GLP-1 receptor agonist, originally developed to treat type 2 diabetes by regulating blood sugar levels